Home News Psoriatic Arthritis Awareness Day: Online forums offer community

Psoriatic Arthritis Awareness Day: Online forums offer community

66
0


September 28, 2022

1 min read


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Online forums, chatrooms and communities are often able help patients with chronic illness find comfort by connecting with other patients sharing their disease burden.

On Psoriatic Arthritis Awareness Day, patients can join online communities to discuss their hardships and triumphs. One resource is the Psoriasis Association, which offers forums for patients with psoriasis and PsA.

Psoriatic arthritis 1
In recognition of Psoriatic Arthritis Awareness Day, Healio has collected its most popular stories related to PsA. Source: Adobe Stock

In recognition of Psoriatic Arthritis Awareness Day, Healio has collected recent news dealing with PsA. Read the most popular stories relating to PsA from 2022 below:

‘Large proportion’ of patients with PsA fail to meet treatment targets

A “large proportion” of patients with psoriatic arthritis fail to reach treatment targets despite medication, with residual musculoskeletal and skin disease frequently observed, according to data published in Rheumatology and Therapy. Read more.

‘One of the few strategy trials in PsA’: CONTROL sheds light on escalation, biologic use

Although there are plenty of drugs to treat psoriatic arthritis, and plenty of studies about those drugs individually, there are fewer trials examining strategies to treat patients who fail to respond to methotrexate in the first line. Read more.

Patients may consider tapering once psoriatic arthritis treatment goals are reached

Patients with psoriatic arthritis may consider tapering once treatment goals are reached, according to guidance from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis published in Nature Reviews Rheumatology. Read more.

Secukinumab minimizes disease activity at 6 months in psoriatic arthritis

Real-world patients with psoriatic arthritis who receive secukinumab for 6 months maintain consistent proportions of minimal disease activity and demonstrate improved patient-reported outcomes, according to data. Read more.

Ixekizumab’s safety profile ‘reassuring’ after 3-year follow-up in psoriatic arthritis

Ixekizumab demonstrates a safety and tolerability profile that is “reassuring” and consistent with previous studies in patients with psoriatic arthritis, according to researchers. Read more.

References:

@PsoriasisUK. https://twitter.com/PsoriasisUK/status/1574439655713521665. Sept. 26, 2022. Accessed Sept. 26, 2022.



Previous articleFeds’ Star Niecy Nash Posted a Rare Instagram Video of Her Wife
Next articleWhy Streamlining Your Clinical Documentation Process Matters